Amgen: Heart Failure trials

The registry lists 10 Heart Failure studies with Amgen as lead sponsor. 1 are open to participants now and 3 have results posted.

Phase 1 2Phase 2 3Phase 3 3Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityRecruitingNCT07037459Phase 3
• A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.CompletedNCT03456856Phase 4Results posted
• Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure PatientsTerminatedNCT03276728Phase 1Results posted
• RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure TrialCompletedNCT00358215Phase 3Results posted
• Heart Failure Study to Evaluate Vital Signs and Overcome Low Use of Guideline-Directed Therapy by Remote MonitoringTerminatedNCT04292275Not applicable
• An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) TrialTerminatedNCT00534456Phase 3
• A Study of Repeat-Dose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control SubjectsCompletedNCT00117247Phase 1/2
• Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and AnemiaCompletedNCT00117234Not applicable
• Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & AnemiaCompletedNCT00086086Phase 2
• Heart Failure and AnemiaCompletedNCT00049985Phase 2